Zymeworks is the first lab tenant improvement in the 3005 First Avenue building for Beacon Capital. The clinical-stage biopharmaceutical company, developing multifunctional biotherapeutics, expanded its current lab and office spaces into the Seattle area with this 6,750 square-foot build-out of Suite 204. Executing this complex project on an aggressive timeline provided insights for Beacon Capital and their multiple scheduled lab improvements. The shell and core upgrade to the building took place concurrently with the Zymeworks improvement, adding a layer of complexity and sequencing for the build-out.
- Status: Completed
- Client: Zymeworks & Beacon Capital
- Architect: SABArchitects
- Structural Engineer: Couglin Porter Lundeen (CPL)
- Size: 6,750 SF
